Week 233 Review - Slight recovery but some big drops too.

Although OPTI:Optibiotix climbed 3p, the portfolio climbed less than that due to some big drops elsewhere, most notably CAML:Central Asia Metals. The value improved by £2,909 and the deficit between cost and value narrowed to £30,281, with total value now at £76,939.

Biggest loser was last week's Share of the Week TRMR:Tremor, which gave up 10% of the 16% rise. I knew it was too good to be true that one of the shares in my trading account might be turning around.

IKA:Ilika was Share of the Week the 2 weeks before that, and just as it was about to go into the black, dropped 9% this week and is looking shaky again. Let's hope it was just profit taking.

TLOU:Tlou Energy gave a rather cautious statement about the progress of de-watering the gas beds which triggered a 9% drop on fears that the flows won't be strong enough for a commercial operation. The statement said all indications were still good, but there's more water than was initially anticipated. The key will be maintaining a consistent flow of gas.

I really don't know what could have justified CAML:Central Asia Metals dropping 7% this week. Copper prices are holding, and they were under-priced before the drop. It hammered my performance this week as I hold a lot of these.

Some rare good news for IQE:IQE which climbed 5% this week. Even my best account is 33% down, with my worst a shocking 62% down. We really need the new reactors producing wafers and the 5g infrastructure orders to start roling in.

OPTI:Optibiotix recovered 3p which was 5%, but are still 19% down and losing £14K. I yearn for some news on SweetBiotix which could be the turning point for the share price.

SBTX:SkinBioTherapeutics also recovered from its sympathy dip by 5% in my ISA and 7% in my SIPP. I'm really considering buying some more of these if I dispose of IKA:Ilika or MMX:Minds + Machines, neither of which I regard as long term investments.

Having said that, MMX:Minds + Machines is Share of the Week after a 6% rise has taken it within 3% of being in the black. Do I wait for a dividend announcement or flog them for a small profit so I can get more SBTX?

It looks a disappointingly tiny blip upwards on this chart.

As long as we're still above the trend line I'll be moderately happy.

The ISA and share accounts look like this

			Weekly Change
Cash	£11.99		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£39,668.89	(-31.3%)	+£1,677.46
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£32.14	(-0.7%)	+£1.34
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£397.19	(8.3%)	-£1.71
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	12.8%		+0%
Compound performance	57%		+0%

Not much to show other than the OPTI:Optibiotix gains caused most of the uplift. Still no shares in profit, but a few very close.

We didn't cross the orange line, but came very close.

Any upward momentum has vanished of the left hand side. It's 12 months of declining value and every time I think a recovery is about to happen, it plunges downwards again.

The SIPP looks like this after week 217

			Weekly Change
Cash	£74.75		+£0
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£35,824.51	(-23.8%)	+£1,283.75
Potential profits	£362.97		-£420.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£13.76	(-0.4%)	+£1.72
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£279.10	(7.1%)	-£1.30
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.2%		-0.1%
Compound performance	47%		+0%

More than half my profits in CAML:Central Asia Metals were wiped out, severely limiting the size of the uplift in value and vexing me considerably.

Below halfway between the injection line and the cost line, which is bad.

Same story of continuous 12 month decline as we see in the ISA.

The trading account looks like this after week 183

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,311.12	(-43.5%)	-£52.18
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.12	(1.1%)	-£0.08
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Most of last weeks gains have gone with big falls for CAML:Central Asia Metals and TRMR:Tremor.

The recovery didn't last.

Some comfort that we're above the trend line.

I've not reported on my magic formula account while I was on holiday, so here's how it performed over the three weeks

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£31,169.62	(+4.4%)	+£68.89
Potential profits	£1,898.42		+£366.96
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

Potential profits are up by £366 but some losses deepened so overall value is only up by £68. Key thing is it's doing better than my real accounts!

The best performing share is an old holding of mine TW.:Taylor Wimpey, up by 26%, closely followed by BDEV:Barratt Developments up 21% and PSN:Persimmon at 20%. All the house builders seem to be on a Brexit roll.

The worst performers are BUR:Burford Capital down 15% and BMN:Bushveld Minerals down 11%, both of which are in the more risky AIM category and which my due diligence may well filter out of any real purchases.

That's the holiday catch-up finished. Let's hope for a nice week and some form of recovery - and dare I hope for a share to go into profit? IKA:Ilika, MMX:Minds + Machines and JLP:Jubilee Metals are all really close.

Week 232 Review - Desperate misery as Optibiotix crashes despite great trading update

Unbelievable - the OPTI:Optibiotix trading update was exactly what was expected, in fact it exceeded expectations as there was an extra £500K owed by companies where we couldn't book the money in the accounts, and that will all come through in H1 of 2020. A 7p drop in share price was the main culprit for this week's drop of £7,380, widening the gap between cost and value to £33,190 and reducing overall value to £74,030.

As mentioned above, the worst performer this week was my biggest holding
OPTI:Optibiotix, dropping 11%. The volatility of this share price is massively frustrating. I know I should relax and be patient, as rewards will be reaped in the future, but it's hard when you are sitting on such big paper losses.

SBTX:SkinBioTherapeutics dropped 10% in sympathy I think, with my SIPP holding 19% down and my ISA holding 40% down on purchase price. There should be a second big deal announced soon, and hopefully this one will promise revenues a bit sooner than the last. Again, as a patient investor it shouldn't be an issue that income is 2 years away. I should just be buying more while they are cheap.

JLP:Jubilee Metals had a good week, climbing 5% and getting to within 3% of being in profit. It's been a long wait, but hope has really been kindled for these.

RDT:Rosslyn Data climbed an impressive 8%, but they are still 67% down and I fear a long way from getting back into the black. This is a very small holding for me though.

IKA:Ilika march forward another 12% and are only down by commission now. If someone had asked me to list the order of the shares that I would expect to return to the black next, this one would have been well down the list.

Share of the week is TRMR:Tremor, which climbed a whopping 16% but is still 32% down in my trading account. I think there's a good chance these are going to recover now.

Back into deep trouble

The only ray of sunshine is we're still above the trend line.

The ISA and share portfolios look like this

			Weekly Change
Cash	£11.99		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£37,991.43	(-34.2%)	-£3,885.76
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£33.48	(-0.7%)	+£1.45
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£398.90	(8.3%)	-£1.73
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	12.8%		-0.2%
Compound performance	57%		+0%

Huge drop, nearly all of which is down to OPTI:Optibiotix.

Only just above the injection line.

Here's the SIPP after week 216

			Weekly Change
Cash	£74.75		+£0
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£34,540.76	(-26.5%)	-£3,575.41
Potential profits	£782.97		+£30.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£15.48	(-0.4%)	+£2.21
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£280.40	(7.2%)	-£1.30
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.3%		+0%
Compound performance	47%		+0%

Same OPTI:Optibiotix problem as the ISA, but CAML:Central Asia Metals climbed a little to raise potential profits by £30

Still a healthy buffer here.

Here's the trading account after week 182

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,363.30	(-41.3%)	+£82.07
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.20	(1.1%)	-£0.09
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Nice week, with lots of rises, but still no prospect of a sale.

It's been going in the right direction for a few weeks now.

I'm reasonably hopeful this lot will turn around.

That's it - no more for this catch-up week.

Week 231 Review - Not a lot happened

I'm on a post-holiday catch-up so the next 2 updates will be brief and just act as a record of where we were at the end of each week. Not a bad week, with portfolio value dropping by £952 and the deficit between cost and value widening to £25,810. Total value is £81,409.

The only big mover was IKA:Ilika, which rose 13% on the back of a 14% rise last week wo earn Share of the Week again.This is now only 12% down.

Here's the ISA and share accounts snapshot

			Weekly Change
Cash	£11.99		-£3.75
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£42,329.65	(-27.5%)	-£452.46
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£34.93	(-0.7%)	+£0.85
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£400.63	(8.3%)	-£1.81
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	13.0%		+0%
Compound performance	57%		+0%

The biggest drop was caused by a 1p fall in OPTI:Optibiotix.

Here's the SIPP after week 215

			Weekly Change
Cash	£74.75		-£16.22
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£38,116.17	(-18.9%)	-£498.64
Potential profits	£752.97		+£60.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.02		+£0.01
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£17.69	(-0.4%)	-£8.77
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0.01
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£283.34	(7.2%)	-£1.33
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.3%		-0.1%
Compound performance	47%		+0%

Similar story to above, but an extra £60 on CAML:Central Asia Metals potential profits and cash and year 5 monthly average profits down due to monthly charges.

Here's the trading portfolio after Week 181

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,281.23	(-44.8%)	-£1.57
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.29	(1.2%)	-£0.09
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Hardly any change here

Week 230 Review - Santa buggered off

It was all looking so positive, even up to this morning, with many of my holdings up significantly. However OPTI:Optibiotix plunged today and ruined the week and what I hoped was a great start to the year. The portfolio value dropped by £5,693 and the deficit between cost and value widened to £24,858 with the overall value dropping to £82,3982.

Worst performer and only major faller was OPTI:Optibiotix which dropped 6p or 9%. That would have cost me £6,300 so it shows the other shares were up by £600. I guess the traders are taking their 10% from when they bought in the late 40's.

JLP:Jubilee Metals started to move again, climbing 6% and this is only 10% down now. The next production figures should see a re-rate.

MMX:Minds + Machines are also starting to motor, with a 9% climb this week meaning they are only 7% down altogether. I really hope they announce a dividend.

Share of the Week is IKA:Ilika which went up by 14% but is still 25% down. I think there's a feeling the car battery technology may pay off so folks are piling in. I'm still keen to pile out as I'm not convinced they have a clue about how to be commercial.

Blip or trend?

At least we're still pulling the trend line flatter.

Here's the performance of the ISA and share accounts

			Weekly Change
Cash	£15.74		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£42,329.65	(-26.7%)	-£3,034.00
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£35.78	(-0.7%)	+£1.70
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£402.44	(8.4%)	-£1.76
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	13.0%		+0%
Compound performance	57%		+0%

Pretty much all of the drop is down to OPTI:Optibiotix, just one week after I was hoping to report that it was back in profit.

Every time is starts looking promising, down we go again.

Still on the right side of the trend line, but in a few weeks there will be nothing left in the black.

The SIPP looks like this after week 214

			Weekly Change
Cash	£90.97		+£0.01
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£38,614.81	(-17.8%)	-£2,694.21
Potential profits	£707.97		+£60.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0.01		+£0.01
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£8.92	(-0.2%)	+£1.79
Total Dividends	£1,899.24		+£0
Total Interest	£0.18		+£0.01
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£283.34	(7.2%)	-£1.33
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.4%		+0%
Compound performance	47%		+0%

Similar story to the ISA, but at least CAML:Central Asia Metals climbed by £60 potential profits, and I spotted 1p interest earned in December - yippee!

Still just above halfway between the orange and red lines

I have almost 6 months before all the above zero values disappear.

The trading account looks like this after week 180

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,282.80	(-44.7%)	+£34.98
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.38	(1.2%)	-£0.11
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.39	(-0.2%)	+£0.01
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Another reasonable week, with small increases in most of the shares. CAML:Central Asia Metals is now only 12% down, so there is a vague hope something could happen here.

Who am I trying to kid - this is still way down on just a few months ago.

Just above the trend line though

Here's the virtual magic formula account

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£30,920.30	(+3.6%)	-£180.43
Potential profits	£1,350.65		-£180.81
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

Quite impressive that the reduction in value is accounted for by a reduction in paper profits down to just a few pence. Best performer is EVR:Evraz, up 12.21% since I "bought" them, and worst performer is BMN:Bushveld Minerals, down by 12.17%.

No updates for a few weeks now as I'm off on holiday, but I'll take weekly snapshots and do a big catch-up at the end of January. By then OPTI:Optibiotix will have issued a trading statement, SBTX:SkinBioTherapeutics may have announced their second deal, JLP:Jubilee Metals may have re-rated, MMX:Minds+Machines may have hinted at a dividend, and TALY:Tally may have lifted their suspension. We can but hope.

Week 229 Review - Santa stuck around

This week was almost as good as last week, with the portfolio increasing in value by £7,517. That reduces the deficit between cost and value to £19,165 and increases the overall value to £88,075. Merry Christmas!

Trading volumes must have been very low this week as everyone was bust eating mince pies. There was only one share that moved by more than 5% and it was OPTI:Optibiotix, climbing 7p which was 10% and storming to Share of the Week for the second week in a row.

Back up to where is was a few months ago. Hopefully this time it will keep going.

That should start to heave the trend line flat

Here's the ISA and share accounts performance

			Weekly Change
Cash	£15.74		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£45,363.65	(-21.5%)	+£4,099.70
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£37.48	(-0.8%)	+£1.88
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£404.20	(8.4%)	-£1.77
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	13.0%		-0.1%
Compound performance	57%		+0%

With so few movers the increased value was all down to OPTI:Optibiotix. This was helped by someone spotting an Instagram post showing a picture of Holland & Barrett's Slimbiome - confirming the first UK retail opportunity and causing a ripple of optimism. Marketing should kick in next week, so let's see what happens.

This is still closer to the injection line than the cost line, so a long way to go yet.

This should really help flatten the trend line, if it lasts.

Here's the SIPP after week 213

			Weekly Change
Cash	£90.96		+£0
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£41,309.02	(-12.1%)	+£3,404.41
Potential profits	£647.97		-£75.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£10.71	(-0.3%)	+£2.68
Total Dividends	£1,899.24		+£0
Total Interest	£0.17		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£284.67	(7.3%)	-£1.35
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.4%		-0.1%
Compound performance	47%		+0%

Similar story to the ISA, with OPTI:Optibiotix accounting for nearly all the rise. Slight downer as the drop in CAML:Central Asia Metals reduced paper profits by £75.

Not too far from getting back into the black.

We've been here before so I'll postpone any celebrations until we go back into the black.

The trading account looks like this after week 179

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,247.82	(-46.2%)	+£13.35
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.49	(1.3%)	-£0.11
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.40	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

Increases in IQE:IQE and TRMR:Tremor were enough to offset the drop in CAML:Cental Asia Metals and increase portfolio value by £13. Still miles away from being able to sell anything though. When I do get to sell something, I need to vow to start trading whatever I buy properly and not treat this as a normal investment account.

Still pretty desperate

Back on the trend line but not yet above it.

Here's my virtual magic formula account performance

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£31,100.73	(+4.2%)	+£145.87
Potential profits	£1,531.46		+£450.59
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

Another good week. I've not really had time to look into any of the companies in my top 30, but it will be at least 4 months until I have any cash to start up the real shares, so plenty of time to get to know them.

There has been one change in the top 30, with BDEV:Barratt Developments dropping out and NXT:Next appearing. It appears the massive post-election spike in BDEV share price has increased the P/E ratio enough for it to no longer class as cheap. There has been no drop in NXT share price though, which has an impressive growth record, but will their return on capital hold up in their next results?

I'll stick to the rules and hold these for a full 12 months before selling anything.

I suspect next week will be another light one for trading, so not anticipating much change. If Holland & Barrett start marketing Slimbiome then we could see another tick up for OPTI:Optibiotix. I only need a 2p rise to be back in the black for this share, and every penny above that is worth £1,050. I'd be happy just to have something other than just CAML:Central Asia Metals showing green on my spreadsheet.

Week 228 Review - Santa Claus has come to town!

At last we have Christmas cheer and bucket-loads to boot. A 10p rally in OPTI:Optibiotix resulted in a rise of £10,443 in portfolio value, narrowed the deficit between cost and value to £26,682 and increased the portfolio value to £80,557. Deep joy.

No big losers this week so even more festive happiness.

IKA:Ilika climbed 7% this week but that wasn't enough to make up for the 9% drop last week. This one may yet make some money if the vehicle batteries come off, but I'm not holding out too much hope.

Share of the Week goes to OPTI:Optibiotix by a country mile, with a 16% increase being worth £10,500 and accounting for all the rise in the portfolio value. In fact there would have been a small loss without it, as many shares had small drops.

Boing!

Take that you evil trend line, and please start changing direction!

The ISA and share accounts look like this

			Weekly Change
Cash	£15.74		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£41,263.95	(-28.6%)	+£5,667.87
Potential profits	£0		+£0
Yr 5 Dividends	£0.63		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£39.36	(-0.8%)	+£2.07
Total Dividends	£1,342.93		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£405.97	(8.4%)	-£1.79
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	13.1%		+0%
Compound performance	57%		+0%

Not much to report apart from a stonking great recovery in value, but still a fair way to go before being in profit, and still no positive sale this year despite being nearly half way through it. I'll be needing IQE:IQE to stage a recovery in order to make some profit as that's the one earmarked for sale.

Back above the injection line, but a long way below the cost line.

It remains to be seen whether this is the start of a recovery or a temporary blip.

The SIPP looks like this after week 212

			Weekly Change
Cash	£90.96		+£0
Portfolio cost	£46,995.31		+£0
Portfolio sell value (bid price - commission)	£37,904.61	(-19.3%)	+£4,783.69
Potential profits	£722.97		+£60.00
Yr 5 Dividends	£0		+£0
Yr 5 Interest	£0		+£0
Yr 5 Profit from sales	£0		+£0
Yr 5 Average monthly cash profit	-£13.39	(-0.3%)	+£4.47
Total Dividends	£1,899.24		+£0
Total Interest	£0.17		+£0
Total Profit from sales	£12,549.10		+£0
Average monthly cash profit	£286.02	(7.3%)	-£1.35
(Sold stocks profit + Dividends - Fees / Months)
Performance/Injection	11.5%		+0%
Compound performance	47%		+0%

Another huge leap in value thanks to OPTI:Optibiotix and a small increase in potential profit thanks to CAML:Central Asia Metals. Average monthly profit for year 5 will remain negative as monthly charges are taken and until I sell something. MMX:Minds+Machines is still top candidate but needs evidence of profits and potentially a maiden dividend to convince the market that their low costs and recurring revenues have a long term future.

Back to half-way between injection and current cost

I need another 10p rise in OPTI:Optibiotix for that to get into profit, but most of the other shares are so bad at the moment it will take 10p on top of that to get back into the black.

Here's the trading account after week 178

		Weekly Change
Cash	£48.24		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,234.47	(-46.8%)	-£7.60
Potential profits	£0		+£0
Year 4 Dividends	£13.20		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£2.60	(1.3%)	-£0.12
Dividends	£47.92		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.40	(-0.2%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)
Performance/Injection	-0.2%		+0%
Compound performance	-1%		+0%

A small loss this week as the drop in IQE:IQE was greater than the rise in CAML:Central Asia Metals. Still no sign of being able to do anything interesting with this cursed account.

No dramas - just serial poor performance

Back below the pitiful trend line

Here's my virtual magic formula account performance

			Weekly Change
Cash	£153.61		+£0
Portfolio cost	£29,846.39		+£0
Portfolio sell value (bid price - commission)	£30,954.86	(+3.2%)	+£230.32
Potential profits	£1,080.87		+£139.41
Year 1 Dividends	£0		+£0
Year 1 Profit	£0		+£0
Yr 1 Average monthly cash profit	£0	(0%)	+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0	(0%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

Portfolio value up by £230 and potential profits up by £139 so about half the rise is reduced losses. Best performing share is EVR:Evraz up 10.92% and worst performing is BMN:Bushveld Minerals which is down 16.57%. Only 6 of the shares are down since I bought them, and 24 are up. At the moment it's doing somewhat better than my real portfolio!

The same 30 companies are still at the top of the list, but the drop in share price has moved CAML:Central Asia Metals up to 31st and it only needs to move 6 places up the P/E ranking to enter the top 30.

KETL:Strix Group is 30th and so in most danger of falling out. At the moment my holding is making £65 (6.55%) profit. The rules of the magic formula are that you hold a share for a year before selling if it drops out of the top 30, but normally you would have bought gradually. My plan is to buy 2 every 4 months when I get my pension transfer, although I may buy some others when I sell existing holdings so I can get to 30 companies a bit quicker, as it will take 4 years at my current rate.

Meanwhile I'll be learning lots about the current top 30 with my virtual portfolio so I'll be ready to avoid any stinkers.